Jiangsu Aidea Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Jiangsu Aidea Pharmaceutical's earnings have been declining at an average annual rate of -57.1%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 5.6% per year.
Key information
-57.1%
Earnings growth rate
-58.6%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 5.6% |
| Return on equity | -9.1% |
| Net Margin | -25.6% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Jiangsu Aidea Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 409 | -105 | 212 | 86 |
| 30 Jun 24 | 354 | -112 | 201 | 80 |
| 31 Mar 24 | 392 | -90 | 204 | 71 |
| 31 Dec 23 | 411 | -76 | 203 | 63 |
| 30 Sep 23 | 412 | -80 | 209 | 52 |
| 30 Jun 23 | 409 | -66 | 209 | 64 |
| 31 Mar 23 | 322 | -101 | 193 | 60 |
| 31 Dec 22 | 244 | -124 | 176 | 64 |
| 30 Sep 22 | 180 | -114 | 149 | 71 |
| 30 Jun 22 | 172 | -111 | 125 | 58 |
| 31 Mar 22 | 213 | -64 | 99 | 53 |
| 31 Dec 21 | 256 | -30 | 86 | 48 |
| 30 Sep 21 | 309 | 17 | 80 | 39 |
| 30 Jun 21 | 317 | 28 | 84 | 37 |
| 31 Mar 21 | 322 | 48 | 84 | 31 |
| 31 Dec 20 | 289 | 40 | 80 | 26 |
| 30 Sep 20 | 327 | 51 | 82 | 30 |
| 30 Jun 20 | 311 | 42 | 72 | 27 |
| 31 Mar 20 | 309 | 31 | 73 | 26 |
| 31 Dec 19 | 345 | 34 | 81 | 28 |
| 31 Dec 18 | 277 | 9 | 75 | 34 |
| 31 Dec 17 | 136 | -38 | 44 | 34 |
Quality Earnings: 688488 is currently unprofitable.
Growing Profit Margin: 688488 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688488 is unprofitable, and losses have increased over the past 5 years at a rate of 57.1% per year.
Accelerating Growth: Unable to compare 688488's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 688488 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.08%).
Return on Equity
High ROE: 688488 has a negative Return on Equity (-9.14%), as it is currently unprofitable.